NAD reviews Colotox
This article was originally published in The Tan Sheet
Executive Summary
The National Advertising Division gives Central Coast Nutraceuticals a second chance to participate in the self-regulatory review process for claims about the firm's Colotox dietary supplement. The Council of Better Business Bureaus' division referred the company to FDA and the Federal Trade Commission in February after the firm failed to respond to NAD's query (1"The Tans Sheet" Feb. 16, 2009, p. 19). Following the referral the advertiser contacted NAD, which reopened the case (2"The Tan Sheet" April 13, 2009, p. 15). NAD says June 3 it determined Central Coast supported claims that Colotox's laxative properties "decrease gas and bloating," "reduce water retention" and relieve constipation. The Phoenix-based firm also supported claims that Colotox increased energy and relieved chronic fatigue. It did not sufficiently support weight-loss claims or claims Colotox removes toxic build-up. The firm says it does not agree with NAD's recommendation to discontinue detoxification claims, but will comply
You may also be interested in...
Nutraceuticals International Spurns NAD Review
Nutraceuticals International says it will answer questions FDA and the Federal Trade Commission may have rather than participate in the National Advertising Division's review of advertising claims for its FucoPure supplement ingredient
NAD Refers Central Coast Nutraceuticals’ Colotox Ads To FTC And FDA
The National Advertising Division will refer Central Coast Nutraceuticals' Colotox advertising to the Federal Trade Commission and FDA for review after the firm failed to respond to an inquiry
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.